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Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality,
but the cellular and molecular mechanisms are still not fully understood. Type II pneumo-
cytes are identified as the synthesizing cells of the alveolar surfactant, which has important
properties in maintaining alveolar and airway stability. Lung surfactant can reduce the
surface tension and prevent alveolar collapse and the airway walls collapse. Pulmonary
surfactant components play important roles in normal lung function and inflammation in
the lung. Surfactant has furthermore been shown to modulate the process of innate host
defense, including suppression of cytokine secretion and transcription factor activation,
in the inflammatory network of COPD. Abnormalities of lung surfactant might be one of
the mechanisms leading to increased airway resistance in COPD. The increased expression
of Granzyme A and B was found in lung tissues of patients with COPD and type II pneumo-
cytes was proposed to be involved in the pathogenesis of COPD. These novel
findings provide new sights into the role of the type II pneumocytes in the pathogenesis
of COPD.
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Chronic obstructive pulmonary disease (COPD) is a disease
characterized by progressive, not fully reversible airflow
limitation, a result of an abnormal inflammatory response
of the lungs to inhaled noxious particles or gasses. Although
the pathology of chronic airway inflammation and emphy-
sema has been extensively explored,1 pathogenesis of COPD
is still under debate. Several mechanisms are involved in
the development of the disease, e.g. inflammation,
imbalance between proteolytic and anti-proteolytic
activity, oxidative stress and apoptosis.2 The observational
studies have shown that inflammatory cells, such as
neutrophils, macrophages, CD8 þ T and B lymphocytes,
increased in airway and lung parenchyma of COPD
patients.3,4 Epithelial cells may also contribute to the
pathogenesis of COPD,5 while the precise mechanism is not
fully elucidated. These cell populations communicate and
interact with the help of altered expression of various
cytokines and adhesion molecules.6Figure 1 Cigarette smoke and noxious particles increase
apoptosis and injury of type II pneumocytes, activating and
enhancing macrophages and phagocytosis of those apoptotic
cells and production and release of proteases. Impaired type II
pneumocytes decreased the production and function of
pulmonary surfactant, leading to the increased activities of
proteases and oxidative stress.Type II pneumocytes
The pulmonary alveoli are lined with two types of cells, the
type I and type II pneumocytes, of whom the type II pneu-
mocyte is a roughly cuboidal cell that is usually found at the
alveolar septal junctions. Type II pneumocytes cover about
5% of the surface area of the lung alveoli and are more
resistant to injury, whereas type I pneumocytes with squa-
mous shape andmore vulnerable cover 95% of the total area.
Type II cells act as the progenitor cells for type I cells. When
type I cells are damaged, type II cells proliferate, migrate,
and spread along the denuded basementmembrane surface,
reform the epithelium, and then differentiate into type I
cells. Thus it is suggested to play an important role in the
repair process of alveolar epithelial barrier. Type II cells
synthesize, store, and secrete pulmonary surfactant, which
reduces alveolar surface tension and stabilizes alveolar
units for efficient gas exchange. Moreover, they secrete
a variety of cytokines and proteins that can modify the
inflammatory response and oxidative stress response and
inhibit fibroblast proliferation and collagen synthesis which
are implicated in the pathogenesis of COPD.7Type II pneumocytes in pathogenesis of COPD
Smoking plays an important role in the pathogenesis of the
destruction in the lung parenchyma and airway inflamma-
tion found in patients with COPD, though only a proportion
(10e20%) of smokers develop progressive airflow limita-
tion.1 As reviewed by Devendra and Spragg, abnormalities
of lung surfactant may be of importance in subacute
pulmonary disease, including COPD.8 Type II Pneumocytes
responsible for the production and secretion of surfactant
were suggested to participate in the development of COPD
(Fig. 1). Cigarette smoking can induce alterations of the
surfactant system, while surfactant homeostasis and func-
tion might be broken down through both direct and indirect
mechanisms.9 Cigarette smoke injuries secretion of type II
pneumocytes, resulting in the reduction of the total
amount of lung surfactant.10 It was reported that the SP-A
levels was significantly lower in patients with COPD and
smokers when compared with nonsmokers.11 The particu-
late phase of cigarette smoke has been demonstrated to
impair surfactant function directly.
Figure 2 Possible role of surfactant dysfunction in the
pathogenesis of COPD.
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reaction of the lungs involving activation of epithelial cells.
Cigarette smoking causes airway inflammation with acti-
vated neutrophils and macrophages.12 In a smoke inhalation
induced acute inflammation model, the expression of p65,
a marker of nuclear factor kappa B activation, was detec-
ted evidently in type II pneumocytes, suggesting that type II
pneumocytes are activated to produce proinflammatory
cytokines after injury.13 On the other hand, Vernooy et al.
recently reported that the level of leptin were markedly
higher in patients with severe COPD and ex-smokers than in
never smokers.14 Leptin is a pleiotropic cytokine and plays
an important role in the regulation of immune responses via
its functional receptor Ob-Rb expressed on bronchial
epithelial cells, type II pneumocytes and macrophages.
Oxidative stress and airway inflammation together form
a vicious cycle, responsible for the progression of the
disease. The oxidative stress could increase the airway
hyperresponsiveness, inflammation and epithelial destruc-
tion and impair the functions of antiproteases and surfac-
tant.15 Type II pneumocytes secrete a variety of
proinflammatory mediators in response to oxidative stress,
which could be amplified by the mediators produced from
alveolar macrophages.16 The nitric oxide synthase localized
in type II pneumocytes was inducible in response to
oxidative stress and increased in patients with severe
COPD. Oxidative stress-induced enzyme e haem oxygenase-
2 was expressed exclusively on type II pneumocytes and
elevated in smokers, indicating the number of type II
pneumocytes increased under this condition.17
Apoptosis is important for eliminating excess activated
inflammatory cells and dead epithelial cells, while excess
apoptosis of airway and alveolar epithelial cells may result
in the reduction of host defenses. Apoptosis of BAL-derived
lymphocytes and brushing-derived airway epithelial cells
significantly increased in COPD.18,19 It is suggested that
destructive process as well as airway and lung tissue
remodeling and fibrosis are involved in the pathogenesis of
COPD. The matrix metalloproteinases (MMPs) and their
inhibitors are a main component in the destructive part of
the remodeling events,20 whereas in the tissue repair/
fibrotic changes, basic fibroblast growth factor and trans-
forming growth factor-beta (TGF-beta) play a main role.
The increased presence of MMP-9 and TGF-beta have found
in bronchial epithelial cells and alveolar type II cells.21,22
On the other hand, type II pneumocytes may play a poten-
tial protective role in the lung repair of this chronic disease
process,24 since type II pneumocytes can proliferate and
transform to type I pneumocytes and can inhibit fibroblast
proliferation and collagen synthesis.23
Pulmonary surfactant and COPD
Surfactant physiology
Lung surfactant is a surface active material that is
synthesized by type II pneumocytes, composed of phos-
pholipids and proteins (10%). Two of the hydrophilic
surfactant-associated proteins, SP-A and SP-D, modulate
host innate and adaptive immune response,25 while the
other two hydrophobic proteins, SP-B and SP-C, play anessential role in reducing surface tension.26 After synthesis,
surfactant is packaged into lamellar bodies and then
secreted into the thin, liquid hypophase that covers the
alveolar epithelium. Surfactant recovered by lung lavage
may be separated into two fractions by centrifugation:
a highly surface active sedimenting fraction termed “large
aggregates” and a poorly surface active, nonsedimenting
“small aggregates”.27 Surfactant not only maintains alve-
olar and airway stability, but also regulates airway liquid
balance and bronchial clearance.28 It is now recognized as
a crucial component in host immune defense, especially SP-
A and SP-D.25
Surfactant dysfunction and pathogenesis of COPD
Varieties of mechanisms are involved in the process of
surfactant modification, for instance, genetic mutation29 or
lack of synthetic substances. The activity of neutrophil
elastase, MMPs, and proteolytic enzymes particularly
augmented by constituents of cigarette smoke (nitrites and
oxidants) subsequently affects surfactant function.30,31
Oxidative stress from an oxidant/antioxidant imbalance
leads to surfactant lipid peroxidation and directly damages
surfactant homeostasis.32,33 There is an evidence of
increased oxidative stress in the airways of patients with
COPD.34 Host defense may be impaired due to the oxidative
damage to functional capacity of surfactant protein D to
agglutinate bacteria33 (Fig. 2).
Biochemical and biophysical dysfunction of pulmonary
surfactant have been reported in various diseases, such as
the acute respiratory distress syndrome, asthma, pneu-
monia, mechanically-ventilated lung injury and COPD.35,36
Lusuardi et al. found an increased ratio of phosphatidyl-
glycerol/cardiolipin and decreased concentrations of total
phospholipids in BAL of 20 smoking, nonasthmatic COPD
patients compared to 5 nonsmoking healthy controls.37 It
was also reported that total phospholipid and surface
activity decreased in BAL fluid in smokers.38 Type II pneu-
mocytes exposed directly to cigarette smoke in culture
decreased secretion of PC.39Analysis of SP-A, SP-B and SP-D
genes in patients with COPD revealed a correlation with the
severity of the disease.40,41 Smokers with COPD had
significantly lower SP-D levels than healthy smokers in
a cross-sectional study.42 Experimental study on lung injury
showed that the susceptibility to ozone-induced airway
inflammation was associated with decreased levels of
surfactant protein D.43 SP deficient mice had an abnormal
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macrophages, increased levels of MMPs and emphysema-
tous changes in the lung parenchyma.44e46 Increased SP-D
level in smoking-induced mouse emphysema could be
interpreted as a protective role in the development of
smoking-induced emphysema.47
The ability to maintain free airflow in narrow conducting
airways of rats was dependent on the quality of surfactant.48
Airway surfactant dysfunction, at least in part, contributes
to increased airway resistance (Fig. 2). Moreover, surfactant
dysfunction could increase pressure gradient across the
alveolar wall resulting in the rupture of the alveolar wall and
the development of emphysema, as extracellular matrix
components of the alveolar wall may be partially damaged in
COPD It was found that surfactant had an unexpected anti-
inflammatory effects.49 SP-D could suppress NF-kB activation
andMMP production in alveolarmacrophages,50 although the
precise role of pulmonary surfactant in the pathogenesis of
airway inflammation remains unclear. There is limited
information on the value of exogenous surfactant treatment
of patients with COPD. Patients with stable chronic bron-
chitis who received aerosolized surfactant improved
pulmonary function and sputum transport by cilia in a dose-
related pattern.51 The exogenous surfactant was used to
treat the patients with severe exacerbation of COPD
requiring mechanical ventilation.52
Granzymes in type II pneumocytes and COPD
Numerous studies showed altered balance of the CD4þ/
CD8þT lymphocyte ratio, especially CD8þT lymphocytes,53
infiltrating in the airways and lung parenchyma. The serine
proteases Granzyme A (GrA) and B (GrB) together with per-
forin are major effector molecules of CD8 þ T lymphocytes
andnatural killer cells. IncreasedGrAandGrBexpressionwas
found in the sputum and/or lung speciments of patients with
COPD. The expression of GAwas significantly higher in type II
Pneumocytes of patients with COPD versus control
subjects.54 GrA is known to stimulate the production of IL-6
and IL-8which increased in the lungs of patientswithCOPD.55
GrA and GrB exert the proteolytic action on extracellular
matrix and may play a role in airway remodeling and tissue
destruction in COPD.56 In adition, perforin-dependent cell
apoptosis initiated by GrA and GrB could target the devel-
opment of tissue destruction.57,58 It is possible that GrA and
GrB are involved in alveolar cell apoptosis, responsible for
the loss of alveolar structures in COPD.
It is also possible that type II Pneumocytes are involve in
the pathogenesis of COPD through the over-expression and
activation of GrA and GrB. There is still no direct evidence
to confirm the precise role of type II pneumocytes in the
COPD. The further study should clarify if type II pneumo-
cytes act as the primary or secondary role in the patho-
genesis of COPD. There is a great need to define the valid
strategies clarify type II pneumocyte dysfunctions in COPD
and the potential as the targeting cell for therapy and.
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